Benefits
Traditional expectorant for cough and chest congestion
Elecampane root has a long European history as an expectorant for chesty coughs and bronchial catarrh, and the British Herbal Pharmacopoeia lists it for those uses at gram-level doses of the dried root. That record describes how the root was used for centuries. It is not proof that it works, and no trial has tested elecampane by itself for cough.
Part of a honey-based children's cough syrup
In one placebo-controlled trial in children aged 3 to 6, a syrup of acacia honey with mallow, elecampane, plantain and helichrysum extracts eased night and day cough sooner than a fructose placebo. The placebo contained no honey, and honey soothes cough on its own, so the result cannot be credited to elecampane. Half of the authors were employees of the company Schwabe Pharma Italia.
Calms airway inflammation signals in cell studies
In human neutrophils and airway cell cultures, alantolactone, the main lactone in elecampane root, lowered release of IL-8, IL-1 beta and TNF-alpha, and elecampane extract made neutrophils less likely to stick to the airway lining. Alantolactone also damped smoke-induced inflammation in bronchial cells. These are laboratory results, not effects measured in people.
Antibacterial lactones against staph in the lab
The root's sesquiterpene lactones, chiefly alantolactone, isoalantolactone and igalan, inhibit Staphylococcus aureus in laboratory tests, which fits the old use of elecampane for chest infections. Test-tube activity does not show that a tea or tincture reaches useful levels in the lungs, and the herb is no substitute for antibiotics when a bacterial infection is diagnosed.
Respiratory claims remain untested in people
Germany's Commission E issued a negative monograph on elecampane in the 1980s, citing insufficient evidence of benefit and the risk of adverse effects, and the root was later left out of ESCOP, WHO and European Medicines Agency herbal monographs. Its main lactone also barely reaches the bloodstream when swallowed, at least in rats, so laboratory findings may not carry over.
Mechanism of action
Sesquiterpene lactones as the active fraction
Alantolactone and isoalantolactone are the root's characteristic eudesmane lactones and the compounds behind most of its laboratory activity. Their reactive alpha-methylene lactone ring is regarded as the key active structure of these compounds, and sesquiterpene lactones are also the main allergens in daisy-family plants.
Cytokine and NF-kB signaling in airway cells
In human bronchial epithelial cells exposed to cigarette smoke extract, alantolactone reduced IL-1 beta, TNF-alpha and IL-6 release, cell death and oxidative stress by activating Nrf2 and heme oxygenase-1 and inhibiting NF-kB. Separately, elecampane extract and compounds lowered neutrophil beta2 integrin, limiting attachment to airway cells.
Demulcent polysaccharides in water extracts
Water extracts of the root are rich in polysaccharides, including inulin-type fructans. In the children's syrup trial the elecampane component was an aqueous extract standardized to at least 30 percent polysaccharides, intended to coat irritated throat tissue as a soothing barrier rather than act like a drug.
Poor oral absorption and CYP3A4 inhibition
In rats, alantolactone broke down in gastrointestinal fluids and was cleared heavily by the liver, giving an oral bioavailability of about 0.3 percent. In human liver microsomes it inhibited the drug-metabolizing enzyme CYP3A4 at low micromolar levels, and CYP2C19 more weakly.
Clinical trials
Randomized, double-blind, placebo-controlled trial of KalobaTUSS, a class IIa medical-device syrup of acacia honey with Malva sylvestris, Inula helenium root, Plantago major and Helichrysum stoechas aqueous extracts, 5 mL four times daily for 8 days (Carnevali I, La Paglia R, Pauletto L, Raso F, Testa M, Mannucci C, Sorbara EE, Calapai G 2021, BMC Pediatr 21(1):29, PMID 33430841). It did not test elecampane alone.
106 children aged 38 to 70 months with acute cough of about three and a half days' duration, seen by pediatricians in Italy after asthma and other airway disease were excluded; 54 received the syrup and 52 placebo.
After 8 days, night-time cough persisted in 7 of 54 children on the syrup versus 22 of 52 on placebo, and daytime cough in 8 of 54 versus 24 of 52; no adverse events were reported. The placebo was a fructose syrup without honey or plant extracts, so honey alone could account for much of the effect. Four of the eight authors were employees of Schwabe Pharma Italia, cough was scored by parents, and the trial was registered retrospectively.